David E. Martin

发表

The Effects of Temperature on Marathon Runners' Performance

David E. Martin, John F. Buoncristiani, David E. Martin, 1999 .

A hypothetical computer to simulate microprogramming and conventional machine language

David E. Martin, Jerry E. Sayers, 1989, SIGM.

A hypothetical computer to simulate microprogramming and conventional machine language

David E. Martin, Jerry E. Sayers, 1988, SGCS.

An Oral Human Drug Absorption Study to Assess the Impact of Site of Delivery on the Bioavailability of Bevirimat

David E. Martin, A. Connor, Philip Evans, 2009, Journal of clinical pharmacology.

Bevirimat: A Novel Maturation Inhibitor for the Treatment of HIV-1 Infection

David E. Martin, K. Salzwedel, G. Allaway, 2008, Antiviral chemistry & chemotherapy.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

David E. Martin, E. Freed, K. Salzwedel, 2006, Virology.

Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat (MPC-4326*), is Determined by Clade- Specific Polymorphisms in Gag CA-SP1

David E. Martin, François Hamy, T. Klimkait, 2009 .

Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice

David E. Martin, J. C. Bare, G. Allaway, 2007, PloS one.

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

David E. Martin, R. Tripp, R. Balyan, 2021, Scientific Reports.

Rifabutin: A New Rifamycin for the Prevention of Atypical Mycobacterial Infection

David E. Martin, R. Raasch, 1994 .

Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

David E. Martin, Judy Doto, C. Ellis, 2008, Clinical therapeutics.

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

David E. Martin, C. Cohen, J. Lalezari, 2011, Journal of acquired immune deficiency syndromes.

Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist

David E. Martin, G. Feuerstein, D. Seiffert, 2003, Platelets.

Resistance to Second-Generation HIV-1 Maturation Inhibitors

David E. Martin, S. Durell, E. Freed, 2018, Journal of Virology.

ANTI-AIDS AGENTS 65: INVESTIGATION OF THE IN VITRO OXIDATIVE METABOLISM OF 3′,4′-DI-O-(–)-CAMPHANOYL-(+)-CIS-KHELLACTONE DERIVATIVES AS POTENT ANTI-HIV AGENTS

David E. Martin, J. Swenberg, K. Lee, 2005, Drug Metabolism and Disposition.

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV

David E. Martin, Chin-Ho Chen, K. Lee, 2005, Expert opinion on investigational drugs.

Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

David E. Martin, Judy Doto, Patrick F. Smith, 2007, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

David E. Martin, J. Marier, L. Pheng, 2011, Antimicrobial Agents and Chemotherapy.

Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males

David E. Martin, Patrick F. Smith, A. Forrest, 2000, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers

David E. Martin, Judy Doto, J. Wilton, 2007, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeﬁciency Virus Maturation, in Healthy Volunteers (cid:1)

David E. Martin, Judy Doto, J. Wilton, 2007 .

Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans

David E. Martin, Patrick F. Smith, A. Forrest, 2000, Antimicrobial Agents and Chemotherapy.

Maturation inhibitors: a new therapeutic class targets the virus structure.

David E. Martin, K. Salzwedel, M. Sakalian, 2007, AIDS reviews.

Interspecies Pharmacokinetics of a Novel Hematoregulatory Peptide (SK&F 107647) in Rats, Dogs, and Oncologic Patients

David E. Martin, J. Nemunaitis, D. Brocks, 1996, Pharmaceutical Research.

Multiple-Dose Pharmacokinetics and Safety of Bevirimat, a Novel Inhibitor of HIV Maturation, in Healthy Volunteers

David E. Martin, Judy Doto, C. Ballow, 2007, Clinical pharmacokinetics.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors

David E. Martin, E. Freed, J. Schneider, 2015, Antimicrobial Agents and Chemotherapy.

Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences

David E. Martin, K. Lee, P. Bullock, 2007, Drug Metabolism and Disposition.

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

David E. Martin, E. Freed, J. Orenstein, 2003, Proceedings of the National Academy of Sciences of the United States of America.